Posted in | News | Nanomedicine

Project Will Advance Promising New RNAi Cancer Therapies

Download PDF Copy

Oct 23 2008

Kylin Therapeutics, Inc., a developer of next-generation RNAi therapeutics, announced the expansion of its research and development efforts.

The project will advance promising new RNAi cancer therapies. This expanded effort will be conducted at Purdue University's Bindley Bioscience Center, and will focus on further validating targeted, systemically delivered cancer therapies utilizing Kylin's proprietary pRNAi platform.

"Our in vivo efforts have shown pRNAi to be a very potent and versatile RNA inducing platform," said Eric Davis, the president and CEO of Kylin. "This expanded effort will enable us to test the flexibility of the pRNAi platform against various cancer targets."

Download PDF Copy

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback

Public Comment

Private Feedback to AZoNano.com

Submit

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.